Literature DB >> 12499236

Moxifloxacin for community-acquired pneumonia.

Bart J A Rijnders.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499236      PMCID： PMC149037          DOI： 10.1128/AAC.47.1.444-445.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  4 in total

1.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors:  M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

3.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.

Authors:  P L Ho; W S Tse; K W Tsang; T K Kwok; T K Ng; V C Cheng; R M Chan
Journal:  Clin Infect Dis       Date:  2001-02-28       Impact factor: 9.079

4.  Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.

Authors:  R Finch; D Schürmann; O Collins; R Kubin; J McGivern; H Bobbaers; J L Izquierdo; P Nikolaides; F Ogundare; R Raz; P Zuck; G Hoeffken
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.